Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Antimicrobial agents and chemotherapy - 1 Mar 2011

Charpentier Charlotte, Roquebert Bénédicte, Delelis Olivier, Larrouy Lucile, Matheron Sophie, Tubiana Roland, Karmochkine Marina, Duval Xavier, Chêne Geneviève, Storto Alexandre, Collin Gilles, Bénard Antoine, Damond Florence, Mouscadet Jean-François, Brun-Vézinet Françoise, Descamps Diane

Abstract excerpt

We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase

Share to Molecular Sequence Data

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 21189351
DOI: 10.1128/AAC.00942-10
PMCID: PMC3067093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21189351-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.PMID 21189351Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.Semantic proximity Read ↗

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Semantic proximity Read ↗

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral TherapySemantic proximity Read ↗

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.Semantic proximity Read ↗

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.Semantic proximity Read ↗

Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to ElvitegravirSemantic proximity Read ↗

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.